Work

Phase 1 first-in-human study of irreversible FLT3 inhibitor FF-10101-01 in relapsed or refractory acute myeloid leukemia.

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.15_suppl.7008

Authors: Mark J. Levis, Catherine Choy Smith, Alexander E. Perl, Gary J. Schiller, Amir Tahmasb Fathi, Gail J. Roboz, Eunice S. Wang, Jessica K. Altman, Makoto Ando, Takeaki Suzuki, Ruth Ann Subach, Gary Maier, Timothy Madden, Mary Johansen, Kin Cheung, Michael R. Kurman

Institutions: Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, University of California, San Francisco, University of Pennsylvania, University of California, Los Angeles, Harvard University, Massachusetts General Hospital, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Weill Cornell Medical Center, Roswell Park Comprehensive Cancer Center, Northwestern University, Fujifilm (Japan)

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3166975658

Cites:

Cited by: 14

Related to: 10